<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857177</url>
  </required_header>
  <id_info>
    <org_study_id>177AMD17019</org_study_id>
    <nct_id>NCT04857177</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, Phase III Clinical Trial To Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, active-controlled, parallel group, Phase III&#xD;
      Clinical Trial To Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of&#xD;
      CKD-701 and Lucentis® in Patients with Neovascular(wet) Age related Macular Degeneration&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomised in a 1:1 ratio to receive either CKD-701 or Lucentis®.&#xD;
      Investigational Products (IP) (CKD-701 or Lucentis®) will be administered once a month during&#xD;
      the loading phase(the first three months), and for the next nine months(PRN phase),&#xD;
      administion will be determined based on the PRN administration criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 19, 2018</start_date>
  <completion_date type="Actual">March 17, 2021</completion_date>
  <primary_completion_date type="Actual">March 17, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients with a decrease in the best-corrected visual acuity (BCVA) score of 15 or fewer letters at 3 months versus baseline.</measure>
    <time_frame>Baseline to 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in the best-corrected visual acuity (BCVA) score from baseline to 3 months, 6 months and 12 months</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with a decrease in the best-corrected visual acuity (BCVA) score of 15 or fewer letters at 6 months, 12 months versus baseline</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with an increase in the best-corrected visual acuity (BCVA) score of 15 or more letters at 3 months, 6 months, 12months versus baseline</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Central Retinal Thickness(CRT) at 1 months, 3 months, 6 months, 12months versus baseline</measure>
    <time_frame>Baseline, 1 months, 3 months, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with the absence of intraretinal fluid and subretinal fluid at 3 months, 6 months, 12months versus baseline</measure>
    <time_frame>3 months, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">312</enrollment>
  <condition>Neovascular(Wet) Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>CKD-701</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: CKD-701 (proposed ranibizumab biosimilar)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lucentis®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Lucentis® (ranibizumab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-701</intervention_name>
    <description>CKD-701 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.</description>
    <arm_group_label>CKD-701</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis®</intervention_name>
    <description>Lucentis® (ranibizumab) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.</description>
    <arm_group_label>Lucentis®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥50 years&#xD;
&#xD;
          2. Presence in the study eye of active subfoveal CNV lesion due to AMD&#xD;
&#xD;
          3. The total lesion size ≤ 12 DA in the study eye&#xD;
&#xD;
          4. The presence of CNV foci of more than 50% of the total lesion area in the study eye&#xD;
&#xD;
          5. The best-corrected visual acuity within a range from 78 to 34 letters (20/32~20/200)&#xD;
             measured using the ETDRS chart in the study eye&#xD;
&#xD;
          6. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any previous anti-vascular endothelial growth factor(anti-VEGF) treatment to treat&#xD;
             neovascular AMD&#xD;
&#xD;
          2. Presence of eye-related inflammation or infection, such as Infectious ophthalmitis,&#xD;
             corneal inflammation, conjunctivitis (including scleromalacia), endocular inflammation&#xD;
&#xD;
          3. Any history or clinical basis of disease affecting the retina except age-related&#xD;
             macular degeneration(AMD), such as diabetic retinopathy, diabetic macular edema&#xD;
&#xD;
          4. Presence of CNV in either eye due to other causes, such as ocular histoplasmosis,&#xD;
             trauma, angioid streaks retinopathy or pathologic myopia&#xD;
&#xD;
          5. Patients with macular abnormalities other than age-related macular degeneration (AMD)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeong Gon Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neovascular(wet) Age related Macular Degeneration</keyword>
  <keyword>CKD-701</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

